On October 1, Dong-A ST (Chairman Eom Dae-sig) announced that the company will cooperate with Ildong Pharmaceutical (Chairman Woong-sup Yoon) for joint sales and marketing of the peptic ulcer treatment ‘Dong-A Gaster Tablet’ through co-promotion.

This is the second time that the two companies have cooperated in the field of digestive medicines following the signing of a co-promotion contract for Motilitone Tablet, a functional indigestion medicine, in January of this year. As the companies achieved good synergy in their joint sales of Motilitone, success in the peptic ulcer treatment market is also expected.

Under the co-promotion agreement, the two companies will conduct joint marketing and sales of Dong-A Gaster Tablet for general hospitals and clinics in Korea. However, ‘Dong-A Gaster Injection’ and ‘Gaster D Tablet’ will be sold exclusively by Dong-A ST as before.

Dong-A Gaster Tablet, an ethical drug (ETC), is a histamine H2 receptor antagonist (H2RA) with Famotidine 20mg. It is effective in treating gastro-duodenal ulcers, reflux esophagitis, upper gastrointestinal bleeding due to peptic ulcer, acute stress ulcer and hemorrhagic gastritis, and Zollinger-Ellison Syndrome, as well as in improving acute exacerbated gastric mucosal lesions (erosion, bleeding, redness, edema) in cases of acute gastritis and chronic gastritis.

According to clinical studies, the Dong-A Gaster Tablet has advantages in terms of its effectiveness in suppressing gastric acid secretion and its duration among the H2RA drug family. Furthermore, there is little possibility of drug interaction, which is also advantageous for a concomitant prescription. The product is proven to be safe and effective as it has been prescribed by medical institutions for many years ever since it received domestic market authorization in 1986.

An executive of Dong-A ST said, “Since we signed the co-promotion agreement last year, our two companies have increased their competitiveness in the market for digestive medicines based on our excellent sales marketing infrastructure. Based on such competitiveness and close cooperation, we will do our best to increase sales of ‘Dong-A Gaster Tablet’ in the market for peptic ulcer treatments.”